

publication was incorporated by reference in the present application (see, e.g., page 5, lines 4-6). The present application claims the benefit of U.S. Provisional Patent Applications No. 60/105,701, filed on 26 October 1998, and No. 60/121,300, filed on 23 February 1999; thus the adenovirus type 5 genome sequence registered as GenBank Accession Number #M73260 was available to the public at least at the time the provisional application was filed.

Accordingly, no new matter has been added by way of this amendment and the entry thereof is respectfully requested.

2. To the Claims.

Claims 1-20, 22-24, and 26-28 are pending in the application. Claims 1-5, 14, 16, and 24 are canceled by this amendment, without prejudice or disclaimer. Claims 6-10, 12, 13, 15, and 17-20 are amended, without prejudice or disclaimer. Cancellation or amendment of these claims is not intended to be an acquiescence in the Office's assessment of those claims in the final Office action, dated 20 April 2005, or the Advisory action, dated 25 July 2005, and applicants expressly reserve the right to bring the subject matter of the original claims again in a subsequent, related application. New claims 29-34 are added by this amendment. No additional fee for the newly presented claims is believed due as the present amendment adds six dependent claims and cancels eight claims (including six dependent claims and two independent claims). After entry of this amendment claims 6-13, 15, 17-20, 22-23, and 26-34 are pending in the application.

The amendments to the claims are presented herein below (after the signature page) in the section titled "Amendments to the Claims."

Support for the amendment to claims 6, 17, and 29 can be found throughout the specification, for example, at the following locations: page 4, lines 4-6; page 16, lines 1-5; Figure 1; and original claims 6 and 17.

Support for the amendment to claims 7, 18, and 30 can be found throughout the specification, for example, at the following locations: page 4, lines 4-6; page 16, lines 5-6; Figure 1; and original claims 7 and 18.

Support for the amendment to claims 8, 19, and 31 can be found throughout the specification, for example, at the following locations: page 4, lines 4-6; page 16, lines 5-6; Figure 1; and original claims 8 and 19.

Support for the amendment to claims 9, 20, and 32 can be found throughout the specification, for example, at the following locations: page 4, lines 4-6; page 16, lines 5-6; Figure 1; and original claims 9 and 20.

Support for the amendment to claims 10, 33, and 34 can be found throughout the specification, for example, at the following locations: page 4, lines 4-6; page 16, lines 5-6; Figure 1; and original claim 10.

Support for the amendment to claim 12 can be found throughout the specification, for example, at the following locations: page 12, lines 10-15 and 29-32; and original claim 14.

Support for the amendment to claim 13 can be found throughout the specification, for example, at the following locations: page 12, lines 10-15 and 29-32.

Support for the amendment to claim 15 can be found throughout the specification, for example, at the following locations: page 12, lines 10-15 and 29-32; and original claim 16.

Accordingly, no new matter has been added by way of this amendment and the entry thereof is respectfully requested.